Verification of Antimicrobial Susceptibility Testing Methods: A Practical Approach

Clinical Microbiology Newsletter

Volumn 35, Issue 13, 2013, Pages 103-109

  Patel, Jean B ^a   Sharp, Susan ^b   Novak Weekley, Susan ^c  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b Northwest Permanente   (United States)

^c SCPMG Regional Reference Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; METICILLIN; VANCOMYCIN;

ACCURACY; ANALYTIC METHOD; ANALYZER; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL SUSCEPTIBILITY TESTING METHOD; ARTICLE; BACTERIUM ISOLATE; CEPHALOSPORIN RESISTANT ENTEROBACTERIACEAE; CLINICAL PROTOCOL; DISK DIFFUSION; DRUG SCREENING; ENTEROBACTERIACEAE; ERYTHROCYTE FRAGILITY; FOOD AND DRUG ADMINISTRATION; INTERMETHOD COMPARISON; LABORATORY TEST; LAW; MEDICAL DOCUMENTATION; MEDICAL ERROR; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OFF LABEL DRUG USE; PATIENT CARE; PRACTICE GUIDELINE; QUALITY CONTROL; REPRODUCIBILITY; VALIDATION PROCESS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84879355307     PISSN: 01964399     EISSN: 18734391     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2013.06.001     Document Type: Article

References (9)

1. Centers for Medicaid and Medicare Services Clinical laboratory improvement amendment 2004, Centers for Medicaid and Medicare Services, Department of Health and Human Services, Washington, DC. http://www.cdc.gov/clia/regs/toc.aspx.
2. CLSI Performance standards for antimicrobial susceptibility testing, 23rd informational supplement. CLSI document M100-S23 2013, Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clark R.B., et al. Cumitech 31A. Verification and validation of procedures in the clinical microbiology laboratory 2009, ASM Press, Washington, DC.
4. FDA Class II special controls guidance document: antimicrobial susceptibility test (AST) systems 2007, Division of Microbiology Devices, Center for Devices and Radiological Health, Food and Drug Administration, Washington, DC. http://www.fda.gov/MedicalDevices/Device%20RegulationandGuidance/GuidanceDocuments/ucm080564.htm.
5. CLSI Development of in vitro susceptibility testing criteria and quality control parameters: approved guideline 2008, Clinical and Laboratory Standards Institute, Wayne, PA. 3rd ed. CLSI document M23-A3.
6. CLSI Performance standards for antimicrobial disk susceptibility tests: approved standard 2012, Clinical and Laboratory Standards Institute, Wayne, PA. 11th ed. CLSI document M02-A11.
7. Jorgensen J.H. Selection criteria for an antimicrobial susceptibility testing system. J. Clin. Microbiol 1993, 31:2841-2844.
8. CLSI Cephalosporin and aztreonam breakpoint revisions fact sheet. CLSI document M100-S20 2010, Clinical and Laboratory Standards Institute, Wayne, PA. http://www.clsi.org/wp-content/uploads/2013/01/CephalosporinAztreonamBreakpointFactSheet.pdf.
9. CLSI CLSI rationale document: carbapenem breakpoints for Enterobacteriaceae 2011, Clinical and Laboratory Standards Institute, Wayne, PA. http://www.clsi.org/wp-content/uploads/2013/01/MicroAST_RationaleDocCarbapenemBreakpointsEnterobacteriaceae_2011.pdf.